Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.56, Implies 599% Upside
Unicycive Therapeutics' average stock price target increased from $28.4 to $29.56 by 9 analysts, with a range of $13 to $42. This implies a 599% upside from the Oct. 6 closing price. The consensus rating remains 'Buy' with all 9 analysts recommending purchase.
How this was made
The 30-second read
Why it matters
The target raise signals modest bullish sentiment but provides little actionable insight given the company's micro‑cap status and lack of new operational news.
Market read
The article offers a minor analyst opinion update with limited trading relevance.
What to watch
No new fundamental data; the change reflects analyst sentiment rather than company performance.
Background
Analyst consensus price target for Unicycive Therapeutics, Inc. was raised from $28.4 to $29.56, implying a 599% upside based on the latest closing price.
Market effects
none
none
none
Counterpoint
Price target upgrades may be overly optimistic for a micro‑cap with limited liquidity.
Key entities
- companyUnicycive Therapeutics, Inc.
Biotech firm whose analyst price targets were updated.
